Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension

AYPAR E., ALEHAN D., KARAGÖZ T., AYKAN H. H., ERTUĞRUL İ.

CARDIOLOGY IN THE YOUNG, vol.28, no.4, pp.542-547, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 4
  • Publication Date: 2018
  • Doi Number: 10.1017/s1047951117002542
  • Journal Name: CARDIOLOGY IN THE YOUNG
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.542-547
  • Hacettepe University Affiliated: Yes

Abstract

Background Macitentan is an orally active, potent, dual endothelin receptor antagonist and is the only registered treatment for pulmonary arterial hypertension that significantly reduced morbidity and mortality in a long-term event-driven study.